Compare Johnson & Johnson (JNJ) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Williams-Sonoma, Inc. — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Johnson & Johnson is far larger — about 22× Williams-Sonoma, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Williams-Sonoma, Inc. for 59 Days on average.
| JNJ | WSM | |
|---|---|---|
Market Cap | $618.09B | $28.15B |
Volume | 6,050,983 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $251.81 |
52-Week Low | $186.00 | $168.64 |
Typical Hold Time | 129 Days | 59 Days |
Enterprise Value | $646.37B | $28.65B |
Dividend Yield | 2.09% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Williams-Sonoma (WSM) trades at $241.78, up 0.55% on the day, reflecting strong momentum near its consensus price target of $246.31. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 14.73% net income margin and consistent earnings beats in recent quarters. Recent news highlights market share gains and profitability improvements, with the company raising full-year guidance after strong Q2 2026 results.
The outlook remains positive given WSM's operational efficiency and dividend growth, though risks include housing market sensitivity and competitive pressures. Analyst consensus leans bullish with 32% buy ratings, but high valuation multiples like a P/E of 24.51 warrant caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
